Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Myeloid 1Gynecologic 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Carcinoma, Neuroendocrine 8Neuroendocrine Tumors 5Adrenocortical Carcinoma 5Small Cell Lung Carcinoma 2Gastro-enteropancreatic neuroendocrine tumor 2Carcinoma, Small Cell 2Carcinoma, Non-Small-Cell Lung 2Somatostatinoma 1Neuroendocrine Neoplasms 1Lung Neoplasms 1Gastrointestinal Neoplasms 1Extrapulmonary Neuroendocrine Cancer 1Carcinoma, Ovarian Epithelial 1Carcinoma 1

Interventions

Everolimus 3Sunitinib 2Octreotide 2repotrectinib 1pralsetinib 1pasireotide 1lutetium Lu 177 dotatate 1epothilone B 1cixutumumab 1belinostat 1azaspirane 1avelumab 1Radiotherapy 1Lutetium-177 1Etoposide 1Doxorubicin 1Cisplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma × Etoposide × Endocrine × Clear all
NCT00926640 2018-10-19

A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
28 enrolled
EndocrineThoracic

Carcinoma, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡